NY-TAKTILE
18.5.2023 21:47:29 CEST | Business Wire | Press release
Taktile, the leading automated decisioning platform, announced the launch of its Data Marketplace as part of its mission to revolutionize how fintechs and banks harness data to make decisions.
The Taktile Data Marketplace is a one-stop ecosystem of leading data providers that enables customers to easily access a global collection of traditional credit, identity, fraud, accounting, open banking, and alternative data sources. By leveraging these data sources, Taktile customers can refine their credit policies and automated decision flows to better identify the right customers and make smarter, more accurate decisions that support profitable growth.
Supported data integrations include: Codat, CRS, NovaCredit, Boniversum, credolab, LexisNexis, Experian, Transunion, Equifax, Creditreform and Belvo.
“Identifying the right data sources for your customer segment has never been more important, but building data integrations in-house is often painful, time-consuming, and resource-intensive,” explained Taktile Co-Founder and CEO Maik Taro Wehmeyer. “Our Data Marketplace makes it easy for risk experts to experiment with various data sources so they can focus on improving their decision accuracy rather than on building integrations.”
On Taktile’s low-code platform, fintechs and traditional financial institutions can easily add new data sources from around the world in minutes through using Taktile’s pre-built integrations that support both B2B as well as B2C use cases. In addition, Taktile already offers functionality today that enables customers to easily connect to any modern third-party API so that users are not constrained by the current offering of off-the-shelf integrations.
The obtained data is well-structured and organized, making it easy to glean aggregate insights, build custom metrics, and identify the right KPIs that take decision accuracy to the next level. Users can also simulate decision outcomes before setting new decision strategies live, empowering them to make informed decisions based on real evidence not speculation.
At a time when profitability is top of mind for fintechs and financial institutions, simplifying data integrations is a powerful advantage. Through rapid experimentation, Taktile customers can uncover the best data sources for their target population and ultimately increase acceptance rates, lower default rates, and offer competitive risk-based pricing–all without requiring any engineering resources.
“In a challenging market, it is lenders' ability to harness data to build the most comprehensive view of their borrowers that gives them the edge,” said Phil Low, Head of Partnerships at Codat. "Now that Codat’s universal API is part of Taktile’s Data Marketplace, Taktile customers can incorporate data from any major accounting, open banking or commerce system into their decisioning engine in a few simple steps. In other words, obtaining that edge just got a lot simpler."
The launch of the Data Marketplace reflects Taktile's commitment to innovation and its ongoing efforts to provide customers with the tools they need to succeed in today's rapidly changing business environment. As part of this commitment, Taktile will rapidly add new global data partners every month and expects to triple the number of providers by the end of the year.
About Taktile
Taktile is a rapidly-growing automated decisioning platform that is revolutionizing how companies harness data to steer their business. Taktile’s low-code platform allows companies to easily build, run and evaluate automated decision flows without requiring developers to write complex code. In a world increasingly run on automated decisions, Taktile makes it easy for credit and data teams to build more accurate decision flows, adapt to change quickly, and, ultimately, improve outcomes. Founded in 2020, Taktile has offices in New York, London and Berlin and is backed by leading VCs, including Index Ventures, Tiger Global, and Y Combinator.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005114/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom